(HealthNewsDigest.com) - LA JOLLA, CALIF. – April 16, 2021 – Scientists at Sanford Burnham Prebys have identified a set of human genes that fight SARS-CoV-2 infection, the virus that causes COVID-19. Knowing which genes help control viral infection can greatly assist researchers’ understanding of factors that affect disease severity and also suggest possible therapeutic options. The genes in question are related to interferons, the body’s frontline virus fighters.
The study was published in the journal
“We wanted to gain a better understanding of the cellular response to SARS-CoV-2, including what drives a strong or weak response to infection,” says Sumit K. Chanda, Ph.D., professor and director of the Immunity and Pathogenesis Program at Sanford Burnham Prebys and lead author of the study. “We’ve gained new insights into how the virus exploits the human cells it invades, but we are still searching for its Achille’s heel so that we can develop optimal antivir
Credit: Dotted Yeti
LA JOLLA, CALIF. - April 16, 2021 - Scientists at Sanford Burnham Prebys have identified a set of human genes that fight SARS-CoV-2 infection, the virus that causes COVID-19. Knowing which genes help control viral infection can greatly assist researchers understanding of factors that affect disease severity and also suggest possible therapeutic options. The genes in question are related to interferons, the body s frontline virus fighters.
The study was published in the journal
Molecular Cell. We wanted to gain a better understanding of the cellular response to SARS-CoV-2, including what drives a strong or weak response to infection, says Sumit K. Chanda, Ph.D., professor and director of the Immunity and Pathogenesis Program at Sanford Burnham Prebys and lead author of the study. We ve gained new insights into how the virus exploits the human cells it invades, but we are still searching for its Achille s heel so that we can develop optimal antivirals.
E-Mail
IMAGE: Sumit Chanda, co-senior study author and director of the Immunity and Pathogenesis Program at Sanford Burnham Prebys. view more
Credit: Sanford Burnham Prebys Medical Discovery Institute
LA JOLLA, CALIF. - March 16, 2021 - A
Nature study authored by scientists at Sanford Burnham Prebys Medical Discovery Institute and the University of Hong Kong shows that the leprosy drug clofazimine, which is FDA approved and on the World Health Organization s List of Essential Medicines, exhibits potent antiviral activities against SARS-CoV-2 and prevents the exaggerated inflammatory response associated with severe COVID-19. Based on these findings, a Phase 2 study evaluating clofazimine as an at-home treatment for COVID-19 could begin immediately.
The virus SARS-CoV-2, which causes COVID-19.
Sanford Burnham Prebys Medical Discovery Institute
Senior study author Sumit Chanda, Ph.D., director of the Immunity and Pathogenesis Program at Sanford Burnham Prebys. Previous Next
Newswise LA JOLLA, CALIF. – Jan 12, 2020 – Scientists at Sanford Burnham Prebys Medical Discovery Institute have identified the sensor in human lungs that detects SARS-CoV-2 and signals that it’s time to mount an antiviral response. The study, published today in
Cell Reports, provides insights into the molecular basis of severe disease and may enable new strategies for the treatment and prevention of COVID-19.
“Our research has shown that MDA-5 is the immune cop that’s tasked to keep an eye out for SARS-CoV-2 and call for back-up,” says Sumit Chanda, Ph.D., director of the Immunity and Pathogenesis Program at Sanford Burnham Prebys and senior author of the study. “MDA-5 recognizes replicating viruses in lung cells and activate